Core Viewpoint - ResMed (RMD) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Group 1: Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in a company's earnings picture, specifically tracking EPS estimates from sell-side analysts [1][2]. - A strong correlation exists between earnings estimate revisions and near-term stock price movements, making the Zacks rating system valuable for investors [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Group 2: ResMed's Earnings Outlook - ResMed is projected to earn $9.48 per share for the fiscal year ending June 2025, indicating no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for ResMed has increased by 0.2%, reflecting a positive outlook for the company's earnings [8]. Group 3: Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [9][10]. - ResMed's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [10].

Zacks Investment Research has recently initiated coverage of Retractable Technologies, Inc. (RVP) , assigning an "Underperform" recommendation to the company's shares. This bearish stance reflects significant concerns over the company’s recent financial performance and operational challenges.Retractable Technologies, based in Little Elm, TX, manufactures and markets safety medical products, predominantly syringes and needles, for the healthcare industry. Its offerings are primarily aimed at reducing needles ...

Have you evaluated the performance of Steris' (STE) international operations during the quarter that concluded in March 2025? Considering the extensive worldwide presence of this medical products maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and grow ...

Q1 2025 Earnings Presentation 1 MICHEL BROUSSET MANUEL MANFREDI CO-FOUNDER & CEO CHIEF FINANCIAL OFFICER 2 DISCLAIMER Cautionary Statement Regarding Forward-Looking Statements All statements in this release that are not historical, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: Waldencast's outlook and guidance for 2025; our ability to deliver financial resu ...

Owens & Minor (OMI) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Good day, and thank you for standing by. Welcome to the Owens and Minor First Quarter twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. And please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jackie Marcus, Investo ...

Core Insights - NN, Inc. reaffirms its full-year adjusted EBITDA outlook for 2025 and sets a free cash flow guidance of $14-$16 million [1][15] - The company reported a net sales decrease of 12.8% year-over-year for Q1 2025, totaling $105.7 million, primarily due to business rationalization and unfavorable foreign exchange effects [5][6] - Adjusted EBITDA for Q1 2025 was $10.6 million, maintaining a margin of 10%, an increase from 9.3% in the prior year [5][8] Financial Performance - Q1 2025 net sales were $105.7 million, down from $121.2 million in Q1 2024, with pro forma net sales decreasing by 1.3% after adjustments [5][7] - The company reported a GAAP loss per share of $(0.23) compared to $(0.34) in Q1 2024, while adjusted net loss per share improved to $(0.03) from $(0.08) [9][33] - Free cash flow for Q1 2025 was a use of cash of $7.1 million, compared to a generation of cash of $0.3 million in the same period last year [9][34] Business Segments - Power Solutions segment net sales for Q1 2025 were $43.5 million, down from $48.2 million in Q1 2024, primarily due to the sale of Lubbock operations and lower volumes [10][11] - Mobile Solutions segment net sales decreased to $62.2 million from $73.1 million in Q1 2024, with losses from operations increasing to $2.7 million [12][13] Strategic Initiatives - The company secured $16.4 million in new business wins during the quarter, contributing to a robust commercial pipeline exceeding $740 million [4][21] - NN, Inc. aims for a $15 million cost reduction in 2025 as part of its operational efficiency initiatives [4][5] - The adjusted EBITDA margin target has been raised to 13-14% over the next five years [5][6] Outlook - For 2025, NN, Inc. expects net sales to range between $430 million and $460 million, with adjusted EBITDA projected between $53 million and $63 million [14][15] - The company anticipates that macroeconomic uncertainties will not significantly impact its operations, maintaining a positive outlook for organic growth and cash flow generation [4][15]

Core Insights - Baxter International reported a revenue of $2.63 billion for the quarter ended March 2025, reflecting a decline of 26.9% year-over-year, while EPS was $0.55 compared to $0.65 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $2.57 billion by 2.09%, and the EPS surpassed the consensus estimate of $0.48 by 14.58% [1] Financial Performance Metrics - Net Sales in Advanced Surgery - International reached $123 million, exceeding the average estimate of $117.52 million, with a year-over-year increase of 6% [4] - Net Sales in Pharmaceuticals - U.S. were $195 million, slightly below the average estimate of $196.51 million, showing a year-over-year growth of 2.1% [4] - Net Sales in Front Line Care - International totaled $75 million, surpassing the average estimate of $69.14 million, with a year-over-year increase of 7.1% [4] - Net Sales in Other - U.S. were reported at $48 million, significantly above the average estimate of $15.59 million, reflecting a year-over-year increase of 336.4% [4] - Total Net Sales in Pharmaceuticals amounted to $581 million, compared to the average estimate of $590.04 million, with a year-over-year change of 0.5% [4] - Net Sales in Other reached $78 million, exceeding the average estimate of $46.71 million, with a year-over-year increase of 387.5% [4] - Net Sales in Front Line Care were $277 million, above the average estimate of $269.11 million, showing a year-over-year increase of 4.5% [4] - Net Sales in Infusion Therapies and Technologies were $994 million, surpassing the average estimate of $975.62 million, with a year-over-year change of 2.9% [4] - Net Sales in Care and Connectivity Solutions reached $427 million, exceeding the average estimate of $416.60 million, with a year-over-year increase of 6.2% [4] - Net Sales in Healthcare Systems and Technologies were $704 million, above the average estimate of $685.71 million [4] - Net Sales in Medical Products and Therapies totaled $1.26 billion, slightly above the average estimate of $1.25 billion [4] - Net Sales in Injectables and Anesthesia reached $335 million, exceeding the average estimate of $330.83 million [4] Stock Performance - Baxter's shares have returned -7.4% over the past month, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Q3 FY25 Earnings Cardinal Health, Inc. May 1, 2025 © 2025 Cardinal Health. All Rights Reserved. 1 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings Cautions Concerning Forward-Looking Statements Q3 Results © 2025 Cardinal Health. All Rights Reserved. 3 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These st ...

Core Viewpoint - Gentex Corporation (GNTX) reported a decline in adjusted earnings per share (EPS) and net sales for the first quarter of 2025, indicating challenges in the automotive products market and an unfavorable product mix [1][2]. Financial Performance - GNTX's adjusted EPS for Q1 2025 was 43 cents, matching the Zacks Consensus Estimate but down 8.5% year over year [1]. - The company reported net sales of $576.8 million, missing the Zacks Consensus Estimate of $587 million and decreasing by 2.3% from the previous year [2]. - Gross margin fell to 33.2%, a decline of 110 basis points from Q1 2024, attributed to lower sales, an unfavorable product mix, and new tariff costs [2]. Segmental Performance - The Automotive segment, which is the largest revenue contributor, had net sales of $563.9 million, down from $577.6 million year over year and below the estimate of $570.4 million [3]. - Auto-dimming mirror shipments in North America decreased by 7% to 3,619,000 units, while international shipments fell by 8% to 7,923,000 units, leading to a total shipment decline of 7% to 11,542,000 units [3]. Other Sales and Products - Other net sales, including dimmable aircraft windows and fire protection products, increased slightly from $12.6 million to $12.9 million but were below the estimate of $15.2 million [4]. - Fire protection sales decreased by 1.5% year over year, and dimmable aircraft window sales fell by 15.5% year over year [4]. Operating Expenses - Total operating expenses rose by 8% year over year to $78.7 million in Q1 2025 [5]. - Engineering and R&D expenses increased to $45.92 million from $42.18 million in the same quarter of 2024, while SG&A expenses decreased to $29.93 million from $30.71 million [5]. Shareholder Returns and Cash Position - GNTX paid a dividend of 12 cents per share and repurchased 3.1 million shares at an average price of $24.52 per share [6]. - As of March 31, 2025, the company had approximately $286.6 million in cash and cash equivalents [6]. 2025 Guidance - GNTX revised its 2025 sales guidance to a range of $2.10-$2.2 billion for the primary market and $50-$120 million for the Chinese market, highlighting exposure to tariffs [6]. - The gross margin is projected to be between 33-34%, down from the previous guidance of 33.5-34.5% [7]. - Capital expenditure is anticipated to be between $100 million and $125 million, and operating expenses are estimated to be in the range of $300-$310 million [7].

The upcoming report from Cardinal Health (CAH) is expected to reveal quarterly earnings of $2.15 per share, indicating an increase of 3.4% compared to the year-ago period. Analysts forecast revenues of $55.03 billion, representing an increase of 0.2% year over year. Analysts forecast 'Segment profit- Pharmaceutical and Specialty Solutions' to reach $635.77 million. Compared to the present estimate, the company reported $580 million in the same quarter last year. Analysts predict that the 'Segment profit- Gl ...